- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Advanced Proteome Therapeutics announced the election of its board of directors form the shareholders annual general meeting and provided an operational update.
Advanced Proteome Therapeutics (TSXV:APC) announced the election of its board of directors form the shareholders annual general meeting and provided an operational update.
As quoted in the press release:
The Company’s management is pleased to provide its shareholders an overview of the progress of the Company during FY 2017.
The Company continues to drive towards the development of their own product suite as well as showing viability of their novel linker technology for licensing purposes. In FY 2017 major strategic and operational changes have taken place to set the stage for a future of rapid growth.
“We are very pleased to state that we have gathered substantial momentum in our programs during 2017 and we have been able to make key structural and operational changes within the organization,” stated Dr. Randal Chase, President and CEO of the Company. “We are now in a position to successfully execute on our growth strategy of partnering our proprietary linker technology with leading institutions around the world, and developing our product suite.”
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.